Skip to main content

Week In Review: Matridx Raises $32 Million For AI/CRISPR-Cas Pathogen Metagenomics Diagnostic Devices

Matridx Biotech of Hangzhou closed a $32 million Series B round to support its pathogen metagenomics devices. GenFleet Therapeutics raised $16 million in a Series B+ round for clinical trials of its two lead oncology candidates in China and the US.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.